Recent Updates
Recently added Catalysts
SNDX Positive Sentiment

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Thursday, February 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Syndax Pharmaceuticals announced its participation in the 2026 Guggenheim Emerging Outlook: Biotech Summit, where CEO Michael A. Metzger will engage in a fireside chat. The event is scheduled for February 12, 2026, and will include a live webcast available on the company's website. Syndax continues to advance its innovative cancer therapies, including FDA-approved treatments.
Price reaction · baseline $20.43 (2026-02-04 close) · hit pre-market · clean, no other SNDX news in the window
day 0 close · peak
-1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Syndax is actively participating in a prominent biotech summit.
  • The company showcases its commitment to innovative cancer therapies.
  • Live webcasts enhance accessibility for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
5.3%
average across 8 past catalysts
Cash runway
~54 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer

Full Press Release Details

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website atwww.syndax.com, where a replay will also be available for a limited time.
About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj®(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.com/or follow the Company onXandLinkedIn.

Syndax ContactsSharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827

SNDX-G

Frequently Asked Questions

When is the Guggenheim Biotech Summit?

The Guggenheim Biotech Summit is scheduled for February 12, 2026.

Who will represent Syndax at the summit?

Michael A. Metzger, the CEO of Syndax, will participate in the event.

How can I watch the fireside chat?

The fireside chat will be available via a live webcast on Syndax's website.

What are Syndax's notable products?

Syndax's pipeline includes FDA-approved Revuforj® and Niktimvo™.

ShareAdd on Google
Tags: SNDX Viatris Investor Conferences Healthcare Syndax Guggenheim biotech summit cancer therapies FDA-approved
Last updated: Feb 5, 2026

Biotech snapshot

Cash runway
$548M liquidity · $10M/mo burn
~54 mo
Low dilution risk
Lead asset
entinostatPhase 1
Epithelial Ovarian Cancer →

Catalyst track record

+133%
best trade around SNDX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for SNDX.

See every catalyst's timing & PoA →